Department of Medical Laboratory Sciences, Faculty of Allied Health Sciences, Kuwait University, Kuwait.
Pathol Res Pract. 2011 Nov 15;207(11):671-3. doi: 10.1016/j.prp.2011.07.013. Epub 2011 Oct 13.
Factor V Leiden (FVL; G1691A) is an autosomal dominant mutation with a high risk for thrombosis. Speculation that founders of FVL lived in the Middle East is supported by a prevalence of FVL that is higher in Arabs residing in Israel, Jordan, Lebanon, and Syria (12-14%) than in other white populations like Europeans (4-5%, up to 15% in the South of Sweden). We sought to verify the appropriate use of skin color as a clinical sign by which Arab individuals in Kuwait are included or excluded from testing for FVL. After institutional approval, 200 healthy Arabs residing in Kuwait consented to participate. Skin type was distinguished for the participants by Fitzpatrick natural skin color classification: 76 (38%) skin type II (white), 96 (48%) Mediterranean skin type IV (brown), and 28 (14%) skin type VI (black). FVL was tested by real-time PCR, and the percentage of carriers was calculated in each group. FVL was positive in 17 (8.5%) of the total subjects: 8 (10.5%) skin type II, 7 (7.3%) skin type IV, and 2 (7.1%) skin type VI. Therefore, FVL shows an even distribution in Arabs, and all Arabs residing in Kuwait should be tested for FVL irrespective of skin color.
因子 V 莱顿突变(FVL;G1691A)是一种常染色体显性突变,具有较高的血栓形成风险。人们推测 FVL 的创始人居住在中东,这一推测得到了支持,因为居住在以色列、约旦、黎巴嫩和叙利亚的阿拉伯人(12-14%)中 FVL 的患病率高于其他白人人群,如欧洲人(4-5%,在瑞典南部高达 15%)。我们试图通过肤色作为临床标志来验证其在科威特的阿拉伯个体是否需要或不需要进行 FVL 检测的合理性。在获得机构批准后,200 名居住在科威特的健康阿拉伯人同意参与研究。通过 Fitzpatrick 自然肤色分类来区分参与者的皮肤类型:76 人(38%)为 II 型(白种人),96 人(48%)为地中海 IV 型(棕色),28 人(14%)为 VI 型(黑色)。通过实时 PCR 检测 FVL,并计算每个组中的携带者比例。在总共 200 名受试者中,有 17 人(8.5%)FVL 阳性:8 人(10.5%)为 II 型,7 人(7.3%)为 IV 型,2 人(7.1%)为 VI 型。因此,FVL 在阿拉伯人中分布均匀,居住在科威特的所有阿拉伯人都应该进行 FVL 检测,而不论肤色如何。